No Data
No Data
UBS Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Cuts Target Price to $390
Bio-Rad Laboratories | 10-Q: Quarterly report
Bio-Rad Laboratories Is Maintained at Outperform by RBC Capital
Bio-Rad Laboratories Analyst Ratings
Bio-Rad Laboratories Up Over 5%, On Track for Largest Percent Increase Since December 2023 -- Data Talk
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
No Data
No Data
affable Blobfish_403 : The intense struggle between political power and market power in the election, the outcome is uncertain, today's debate is a major highlight.
章允量 :
104476495 : hi